

GenCore version 5.1.4-p5.4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 8, 2003, 14:25:27 ; Search time 75 Seconds

(without alignments)
968,288 Million cell updates/sec

Title: US-09-001-737-8

Sequence: 1 MAKEIFSADARAAVAVRGVD.....TPAPAMPAGMDPGMGNGMG 545

Scoring table: OLIGO
Gapop 60.0, Capext 60.0

Searched: 908470 seqs, 133250620 residues

Word size: 8

Total number of hits satisfying chosen parameters: 350

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Listing first 1000 summaries

Database:

A: Geneseq-101002:*

1:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:*
2:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:*
3:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:*
4:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:*
5:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:*
6:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:*
7:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:*
8:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:*
9:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:*
10:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:*
11:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:*
12:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:*
13:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:*
14:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:*
15:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:*
16:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:*
17:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:*
18:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:*
19:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:*
20:	/SID52/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:*
21:	/SID52/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:*
22:	/SID52/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:*
23:	/SID52/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	545	100.0	545	20	AAV23904
2	538	98.7	545	23	ABP28529
3	78	14.3	545	23	ABP28528
4	70	12.8	540	22	AAAM01101
5	70	12.8	541	20	AAV23902
6	70	12.8	641	22	ABBS1619
7	56	10.3	542	23	ABBS1701
8	31	5.7	542	23	ABBA4241
9	26	4.8	539	20	AAV23916
10	24	4.4	224	20	AAV37100

11	24	4.4	419	18	AAV10977	Dihydrofolate redu
12	24	4.4	419	18	AAV11865	DHFR/Polypeptide B
13	24	4.4	419	12	AAV13337	Hypr protein Chl
14	24	4.4	544	16	AAV67383	C. psittaci Hypr g
15	24	4.4	544	18	AAV10975	Chlamydia pneumoni
16	24	4.4	544	18	AAV11865	Polypeptide B. Ch
17	24	4.4	544	20	AAV23905	Amino acid sequenc
18	24	4.4	544	22	AAV34735	Amino acid sequenc
19	24	4.4	544	23	AAE11757	Chlamydia pneumoni
20	24	4.4	545	21	AAV94272	Chlamydia pneumoni
21	24	4.4	545	21	AAV19080	Amino acid sequenc
22	24	4.4	704	18	AAV10976	Amino acid sequenc
23	24	4.4	547	18	AAV11864	Dihydrofolate redu
24	23	4.2	547	22	AAV69060	DHFR/Polypeptide B
25	23	4.2	574	22	AAV69061	Pseudomonas expressio
26	23	4.2	612	22	AAV63908	ptichinib expressio
27	21	3.9	301	22	AAV83041	S. epidermidis ope
28	21	3.9	539	22	AAV81848	S. epidermidis ope
29	21	3.9	541	20	AAV23917	Amino acid sequenc
30	21	3.9	545	20	AAV23930	Amino acid sequenc
31	20	3.7	309	19	AAV60146	Consensus mfn act
32	20	3.7	309	20	AAV14893	M. vaccae antigen
33	20	3.7	309	23	AAV73499	Amino acid sequenc
34	20	3.7	327	20	AAV14910	M. vaccae GroEL hom
35	20	3.7	327	23	AAV73516	Amino acid sequenc
36	20	3.7	523	19	AAV60144	M. vaccae GroEL hom
37	20	3.7	523	20	AAV14891	M. vaccae antigen
38	20	3.7	523	23	AAV73497	Amino acid sequenc
39	20	3.7	539	20	AAV23919	M. vaccae GroEL hom
40	20	3.7	540	9	AAV81351	Amino acid sequenc
41	20	3.7	540	16	AAV81610	Sequence of Mycob
42	20	3.7	540	18	AAV32100	Mycobacterium tube
43	20	3.7	540	19	AAV4702	Mycobacterium sp. h
44	20	3.7	540	18	AAV4702	Mycobacterium tube
45	20	3.7	540	21	AAV23911	Amino acid sequenc
46	20	3.7	540	22	AAV93332	Amino acid sequenc
47	20	3.7	540	22	AAE11755	Mycobacterium tube
48	20	3.7	540	22	AAV81118	Mycobacterium tube
49	20	3.7	540	22	AAV31606	Amino acid sequenc
50	20	3.7	540	23	AAV76510	M. leprae 65kDa at
51	20	3.7	540	23	AAV76511	M. tuberculosis 65
52	20	3.7	540	23	AAV76519	Mycobacterium 65
53	20	3.7	540	23	AAV76194	Mycobacterium lepr
54	20	3.7	540	23	AAV50750	Mycobacterium tube
55	20	3.7	541	16	AAV67384	M. leprae GroEL g
56	20	3.7	541	20	AAV14909	Amino acid sequenc
57	20	3.7	541	20	AAV23910	Amino acid sequenc
58	20	3.7	541	20	AAV23913	Amino acid sequenc
59	20	3.7	541	23	AAV73515	Amino acid sequenc
60	20	3.7	544	18	AAV32059	M. vaccae GroEL hom
61	20	3.7	544	9	AAV80215	Mycobacteria sp. h
62	20	3.7	572	11	AAV04716	Sequence of Mycob
63	20	3.7	573	11	AAV04715	Amino acid sequenc
64	20	3.7	573	16	AAV64765	Amino acid sequenc
65	20	3.7	573	16	AAV64765	M. leprae 65 kDa p
66	20	3.7	588	9	AAV80364	M. tuberculosis 65
67	20	3.7	638	21	AAV37909	M. leprae 65kD ant
68	20	3.7	639	22	AAV31609	Heat shock protein
69	20	3.7	648	22	AAV31609	Amino acid sequenc
70	20	3.7	948	22	AAV31614	Amino acid sequenc
71	18	3.3	948	22	AAV31611	Amino acid sequenc
72	18	3.3	18	17	AAV34845	peptide from 11bra
73	18	3.3	18	18	AAV43523	Mycobacteria sp. h
74	18	3.3	18	18	AAV43527	Mycobacteria sp. h
75	18	3.3	18	18	AAV88287	Hsp-65 peptide epi
76	18	3.3	18	18	AAV88286	Hsp-65 peptide epi
77	18	3.3	24	22	AAV88285	Hsp-65 peptide epi
78	18	3.3	26	22	AAV88310	Hsp-65 peptide epi
79	18	3.3	540	23	AAV23960	Hsp-65 peptide epi
80	17	3.1	544	23	AAV20707	Straphylococcus epi
81	17	3.1	17	22	AAV88298	Francisella tulare
82	17	3.1	23	22	AAV88295	Hsp-65 peptide epi
83	17	3.1	539	20	AAV23914	Hsp-65 peptide epi
	17	3.1	539	23	AAV97744	Amino acid sequenc
	17	3.1	539	23	AAV98656	Mycobacterium tube

84	17	3.1	548	17	AAR94368	Brevibacterium fla
85	17	3.1	548	22	AA692732	C. glutamicum prote
86	17	3.1	549	21	AA996472	B. pseudomallei Gr
87	16	2.9	16	17	AAR94778	Peptide from libra
88	16	2.9	16	18	AAW43456	Mycobacteria sp. h
89	16	2.9	19	17	AAR94827	Peptide from libra
90	16	2.9	19	18	AAW43505	Mycobacteria sp. h
91	16	2.9	51	22	AAB73742	Chaperone cpn60 pr
92	16	2.9	52	13	AAR20195	Heat shock protein
93	16	2.9	103	21	AAB41321	Human ORF1085
94	16	2.9	103	23	ABP03750	Human ORF1085
95	16	2.9	112	19	AAW60130	M. vaccae GroEL-ho
96	16	2.9	112	20	AAW44876	M. vaccae GroEL-ho
97	16	2.9	112	23	ABW34482	M. vaccae GroEL-ho
98	16	2.9	118	23	ABP06879	Human ORF protein
99	16	2.9	215	19	AAW60145	M. vaccae GroEL-ho
100	16	2.9	215	20	AAW14892	M. vaccae GroEL-ho
101	16	2.9	215	23	ABW34488	M. vaccae GroEL-ho
102	16	2.9	295	22	AAB31615	M. vaccae GroEL-ho
103	16	2.9	440	13	AAR23362	M. vaccae GroEL-ho
104	16	2.9	539	20	AAW23906	M. vaccae GroEL-ho
105	16	2.9	540	13	AAR23363	M. vaccae GroEL-ho
106	16	2.9	544	21	AAW57475	Neisseria gonorrhe
107	16	2.9	544	21	AAW57477	Neisseria meningit
108	16	2.9	545	20	AAW33915	Neisseria meningit
109	16	2.9	548	18	AAW16678	Lawsonia intracell
110	16	2.9	15	17	AAR97488	Mycobacterium heat
111	16	2.9	15	23	AAW99970	Mycobacterium lepa
112	16	2.9	19	17	AAR94871	Peptide from libra
113	16	2.9	19	18	AAW33549	Mycobacteria sp. h
114	16	2.9	20	18	AAW33549	Human heat shock p
115	16	2.9	20	18	AAW33549	Human hsp60 peptid
116	16	2.9	152	23	ABP42395	Human ovarian anti
117	16	2.9	160	19	AAW61375	GroEL apical domai
118	16	2.9	160	19	AAW65071	E. coli GroEL prot
119	16	2.9	186	19	AAW61377	GroEL apical regio
120	16	2.9	186	19	AAW65069	E. coli GroEL N-te
121	16	2.9	544	20	AAW33903	Streptococcus pyog
122	16	2.9	545	20	AAW33903	Streptococcus pneu
123	16	2.9	547	16	AAW67381	L. pneumophila Hcp
124	16	2.9	547	16	AAW67385	Mitochondrial prot
125	16	2.9	547	23	AAW76192	Human PI protein (
126	16	2.9	548	18	AAW77882	E. coli GroEL gene
127	16	2.9	548	19	AAW61378	E. coli GroEL prot
128	16	2.9	548	19	AAW65070	E. coli GroEL prot
129	16	2.9	548	20	AAW23908	Amino acid sequenc
130	16	2.9	548	20	AAW95001	MO9902989 Seg ID 1
131	16	2.9	548	21	AAW95621	Escherichia coli g
132	16	2.9	548	22	AAW50536	Escherichia coli g
133	16	2.9	549	20	AAW23909	Amino acid sequenc
134	16	2.9	559	16	AAW64764	E. coli GroEL prot
135	16	2.9	573	11	AAW04713	Amino acid sequenc
136	16	2.9	573	18	AAW12345	Human heat shock p
137	16	2.9	573	18	AAW12345	Human heat shock p
138	16	2.9	573	18	AAW12345	Human heat shock p
139	16	2.9	573	19	AAW01657	Human heat shock p
140	16	2.9	573	19	AAW56120	Human heat shock p
141	16	2.9	573	20	AAW23926	Amino acid sequenc
142	16	2.9	573	21	AAW93333	Amino acid sequenc
143	16	2.9	573	21	AAW93333	Amino acid sequenc
144	16	2.9	573	22	AAW58685	Drosophila melanog
145	16	2.9	573	22	AAW58685	Drosophila melanog
146	16	2.9	573	22	AAW58685	Drosophila melanog
147	16	2.9	573	22	AAW58685	Drosophila melanog
148	16	2.9	573	22	AAW58685	Drosophila melanog
149	16	2.9	573	22	AAW58685	Drosophila melanog
150	16	2.9	573	22	AAW58685	Drosophila melanog
151	16	2.9	573	22	AAW58685	Drosophila melanog
152	16	2.9	573	22	AAW58685	Drosophila melanog
153	16	2.9	573	22	AAW58685	Drosophila melanog
154	16	2.9	573	22	AAW58685	Drosophila melanog
155	16	2.9	573	22	AAW58685	Drosophila melanog
156	16	2.9	573	22	AAW58685	Drosophila melanog

230	11	2.0	19	22	AA88291	Hsp-65 peptide epi
231	11	2.0	20	16	AA81611	Heat shock protein
232	11	2.0	22	21	AA193328	Amino acid sequenc
233	11	2.0	65	20	AAW8995	Expressed antigen
234	11	2.0	99	21	AA12294	Zea mays protein f
235	11	2.0	104	21	AA12293	Zea mays protein f
236	11	2.0	114	11	AA807688	Mycobacterial 65KD
237	11	2.0	114	11	AA807689	Mycobacterial 65KD
238	11	2.0	114	11	AA807690	Mycobacterial 65KD
239	11	2.0	118	22	AAU02875	Synthetic autoant
240	11	2.0	120	23	AA114677	M. vaccae 65Kd he
241	11	2.0	120	23	AA873483	M. vaccae 65Kd he
242	11	2.0	135	21	AA844098	Human cancer assoc
243	11	2.0	145	21	AA844097	Human cancer assoc
244	11	2.0	156	21	AA12292	Zea mays protein f
245	11	2.0	177	21	AA800869	Human secreted pro
246	11	2.0	212	22	AA863522	Human gastric can
247	11	2.0	247	22	AA863519	Human gastric can
248	11	2.0	252	22	AA814357	Novel human diagn
249	11	2.0	258	20	AA137099	Amino acid sequenc
250	11	2.0	261	22	AAU02079	Synthetic multi-ta
251	11	2.0	342	22	AA814356	Novel human diagn
252	11	2.0	397	21	AA853326	Arabidopsis thalia
253	11	2.0	412	21	AA849547	Arabidopsis thalia
254	11	2.0	423	21	AA853325	Arabidopsis thalia
255	11	2.0	443	21	AA849136	Arabidopsis thalia
256	11	2.0	446	21	AA850252	Arabidopsis thalia
257	11	2.0	459	22	AAU02077	Synthetic multi-ta
258	11	2.0	464	22	AAU56773	Proplionlbacterium
259	11	2.0	469	21	AA849135	Arabidopsis thalia
260	11	2.0	477	21	AA819772	Arabidopsis thalia
261	11	2.0	477	21	AA850259	Arabidopsis thalia
262	11	2.0	536	21	AA849134	Arabidopsis thalia
263	11	2.0	541	21	AA850251	Arabidopsis thalia
264	11	2.0	568	20	AA823924	Arabidopsis thalia
265	11	2.0	586	21	AA819771	Amino acid sequenc
266	11	2.0	586	21	AA850258	Arabidopsis thalia
267	11	2.0	611	21	AA819770	Arabidopsis thalia
268	11	2.0	611	21	AA850257	Arabidopsis thalia
269	11	2.0	611	21	AA850257	Arabidopsis thalia
270	11	2.0	650	21	AA850250	Drosophila melanog
271	11	1.8	10	22	AA888269	Hsp-65 peptide epi
272	11	1.8	10	22	AA888290	Hsp-65 peptide epi
273	11	1.8	10	22	AA888299	Hsp-65 peptide epi
274	11	1.8	15	17	AA87498	Mycobacterial heat
275	11	1.8	16	17	AA894826	Peptide from libra
276	11	1.8	16	17	AA894870	Peptide from libra
277	11	1.8	16	18	AAW43548	Mycobacteria sp. h
278	11	1.8	16	18	AAW43504	Peptide from libra
279	11	1.8	17	17	AA894852	Peptide from libra
280	11	1.8	17	18	AAW43530	Mycobacteria sp. h
281	11	1.8	18	22	AA888292	Hsp-65 peptide epi
282	11	1.8	576	20	AA823928	Amino acid sequenc
283	11	1.8	577	20	AA823922	Amino acid sequenc
284	11	1.8	577	20	AA823927	Amino acid sequenc
285	10	1.8	587	20	AA823929	Bacterial conserve
286	9	1.7	9	22	AAU69053	Hsp-65 peptide epi
287	9	1.7	9	22	AA888229	Hsp-65 peptide epi
288	9	1.7	9	22	AA888230	Hsp-65 peptide epi
289	9	1.7	9	22	AA888235	Hsp-65 peptide epi
290	9	1.7	9	22	AA888279	Hsp-65 peptide epi
291	9	1.7	9	23	AAU95802	Immunogenic peptid
292	9	1.7	15	16	AA81615	Heat shock protein
293	9	1.7	17	17	AA894783	Peptide from libra
294	9	1.7	17	17	AA894843	Peptide from libra
295	9	1.7	17	18	AAW43521	Mycobacteria sp. h
296	9	1.7	17	18	AAW43461	Mycobacteria sp. h
297	9	1.7	18	17	AA894790	Peptide from libra
298	9	1.7	18	18	AAW43468	Mycobacteria sp. h
299	9	1.7	19	17	AA894854	Peptide from libra
300	9	1.7	19	18	AAW43454	Mycobacteria sp. h
301	9	1.7	19	18	AAW43532	Mycobacteria sp. h
302	9	1.7	20	18	AAW33044	Human heat shock p

303	9	1.7	20	18	AAW12352	Human hsp60 peptid
304	9	1.7	114	11	AA807693	Mycobacterial 65KD
305	9	1.7	558	22	AA870885	Drosophila melanog
306	8	1.5	9	22	AA888282	Hsp-65 peptide epi
307	8	1.5	9	23	AAE19467	Mycobacterium sp.
308	8	1.5	9	23	AAE19468	Mycobacterium sp.
309	8	1.5	13	19	AAW54696	Peptide from hsp65
310	8	1.5	15	16	AA81623	Heat shock protein
311	8	1.5	15	16	AA81623	Heat shock protein
312	8	1.5	15	17	AA894847	Peptide from libra
313	8	1.5	15	18	AA894874	Peptide from libra
314	8	1.5	15	18	AAW43552	Mycobacteria sp. h
315	8	1.5	15	18	AAW43525	Mycobacteria sp. h
316	8	1.5	15	18	AAE19455	Mycobacteria sp. h
317	8	1.5	16	17	AA894875	Mycobacteria sp. h
318	8	1.5	16	17	AAW43553	Peptide from libra
319	8	1.5	16	22	AA888293	Hsp-65 peptide epi
320	8	1.5	19	17	AA894784	Peptide from libra
321	8	1.5	19	18	AAW43462	Mycobacteria sp. h
322	8	1.5	26	22	AA888309	Hsp-65 peptide epi
323	8	1.5	72	21	AA833002	Arabidopsis thalia
324	8	1.5	93	23	ABP07535	Human OREX protein
325	8	1.5	122	22	ABP03141	Human musculoskele
326	8	1.5	134	21	AA833001	Arabidopsis thalia
327	8	1.5	156	20	AAW97723	Staphylococcus aur
328	8	1.5	244	21	AA835964	Zea mays protein f
329	8	1.5	246	20	AA160028	Human endometrium
330	8	1.5	246	22	AAU45922	Proplionlbacterium
331	8	1.5	256	22	AAU67775	Proplionlbacterium
332	8	1.5	287	22	AAU66503	Proplionlbacterium
333	8	1.5	338	21	AA835963	Zea mays protein f
334	8	1.5	364	21	AA835962	Zea mays protein f
335	8	1.5	440	21	AA800061	Herbicidially activ
336	8	1.5	524	23	AB891959	VR2 polypeptide.
337	8	1.5	533	23	AA885988	Amino acid sequenc
338	8	1.5	545	20	AAW67800	Thermococcus sp. K
339	8	1.5	546	18	AAW26335	KOD-1 heat shock p
340	8	1.5	546	20	AAW67798	Thermococcus sp. K
341	8	1.5	548	20	AAW67797	Thermococcus sp. K
342	8	1.5	549	20	AAW67799	Thermococcus sp. K
343	8	1.5	552	22	AAW67798	Thermococcus sp. K
344	8	1.5	1106	22	AAU03552	Putative P. abyssi
345	8	1.5	1191	21	AA846051	Human protein kina
346	8	1.5	1195	21	AA846050	Arabidopsis thalia
347	8	1.5	1325	21	AA846049	Arabidopsis thalia
348	8	1.5	1422	22	ABG02345	Novel human diagn
349	8	1.5	1504	22	AB860358	Arabidopsis thalia
350	8	1.5	1975	22	AB862094	Drosophila melanog

ALIGNMENTS

RESULT 1
 ID AA123904 standard; Protein; 545 AA.
 AC AA123904;
 XX
 DT 22-SEP-1999 (first entry)
 XX
 DE Streptococcus pyogenes heat shock protein (Hsp)60-2.
 XX
 KW Heat shock protein; Hsp60-2; Immune response; Immunological carrier;
 XX Cancer control; tumour; sarcoma; cancer; gene therapy.
 OS Streptococcus pyogenes.
 XX
 PN MO9935270-A1.
 XX
 PD 15-JUL-1999.
 XX
 PF 29-DEC-1998; 98MO-CA01203.

5 IKESADARAAMRGVMDLADTVKVTIGPKGRNVYLEKAFGSPPLITNGVTIAKEIELEDH 64
|||||
7 IKESADARAAMRGVMDLADTVKVTIGPKGRNVYLEKAFGSPPLITNGVTIAKEIELEDH 66
|||||

QY 65 FENMGAKLVSEVASKTNDIAGDCTTATVLTQAIHSEGLKNVAGANPIGIRRGIEPTATA 124
 DB 67 FENMGALVSEVASKTNDIAGDCTTATVLTQAIHSEGLKNVAGANPIGIRRGIEPTATA 126
 QY 125 TAVEALKAIAPVSKGEALIAQVAAVSSREKVEYISEAMERVNGDVTITIEESGMETE 184
 DB 127 TAVEALKAIAPVSKGEALIAQVAAVSSREKVEYISEAMERVNGDVTITIEESGMETE 186
 QY 185 LEVEEGNPGRCGLSYMTDNEKRVADLENPFLITDKVSNIOIILPLEEVLTNRP 244
 DB 187 LEVEEGNPGRCGLSYMTDNEKRVADLENPFLITDKVSNIOIILPLEEVLTNRP 246
 QY 245 LLIIADVDGEALPTLVLNKIRGFENNVAVKAPGFGDRRKAMEIDAIITGGVTIEDLG 304
 DB 247 LLIIADVDGEALPTLVLNKIRGFENNVAVKAPGFGDRRKAMEIDAIITGGVTIEDLG 306
 QY 305 LEIKDATMTALGOAKITVDKSTIYVSGSSSAIANRIALKSOLLETTSDPDRKLO 364
 DB 307 LEIKDATMTALGOAKITVDKSTIYVSGSSSAIANRIALKSOLLETTSDPDRKLO 366
 QY 365 ERLAKLAGVAVIKVGAFTETALKEMLRIEDALNATRAAVEGIVAGGTAITVIEKV 424
 DB 367 ERLAKLAGVAVIKVGAFTETALKEMLRIEDALNATRAAVEGIVAGGTAITVIEKV 426
 QY 425 AALEEGDATTGRNIYLRALPEPVROIALNAGYEGSVYIDKLNSPAGTGFMATGEVND 484
 DB 427 AALEEGDATTGRNIYLRALPEPVROIALNAGYEGSVYIDKLNSPAGTGFMATGEVND 486
 QY 485 MITGTIIDPVKVTTRSLAONASVSLITTEAVVANKPEPATAPAMPAGMDPGMGG 542
 DB 487 MITGTIIDPVKVTTRSLAONASVSLITTEAVVANKPEPATAPAMPAGMDPGMGG 544
 RESULT 3
 ABP28528
 ID ABP28528 standard; Protein: 540. AA.
 AC ABP28528;
 DT 02-JUL-2002 (first entry)
 DE Streptococcus polypeptide SEQ ID NO 6232.
 XX Streptococcus; GAS; GBS; group B streptococcus; Streptococcus agalactiae;
 KM group A streptococcus; Streptococcus pyogenes; antibacterial;
 KM antiinflammatory; infection; vaccine; meningitis; gene therapy.
 OS Streptococcus agalactiae.
 XX
 FN WO200234771-A2.
 PD 02-MAY-2002.
 PF 29-OCT-2001; 2001WO-GB04789.
 PR 27-OCT-2000; 2000GB-0026333.
 PR 24-NOV-2000; 2000GB-0028727.
 PR 07-MAR-2001; 2001GB-0005640.
 PA (CHIR-) CHIRON SPA.
 PA (GENO-) INST GENOMIC RES.
 PI Telford J, Masignani V, Margarit Ros YI, Grandi C, Fraser C;
 PI Tettelin H;
 XX
 DR WPI: 2002-352536/38.
 DR N-PSDB: ABN69159.
 XX New Streptococcus protein for the treatment or prevention of infection
 PT or disease caused by Streptococcus bacteria, such as meningitis, and
 PT for detecting a compound that binds to the protein -
 XX

PS Claim 1; Page 3785; 4525pp; English.
 XX
 CC The invention relates to a protein (ABP25413-ABP30895) from group B
 CC Streptococcus/GBS (Streptococcus agalactiae) or group A streptococcus/GAS
 CC (Streptococcus pyogenes), comprising one of 5483 sequences (S1), given in
 CC the specification. The proteins have antibacterial and antiinflammatory
 CC activity (I), nucleic acids encoding (II), ABN6044-ABN71526 and
 CC antibodies that bind (I) are used in the manufacture of medicaments for
 CC the treatment or prevention of infection or disease caused by
 CC Streptococcus bacteria, particularly S. agalactiae and S. pyogenes;
 CC Nucleic acids encoding (I) are used to detect Streptococcus in a
 CC biological sample. (I) is used to determine whether a compound binds to
 CC (I). A composition comprising (I) or a nucleic acid encoding (I), may be
 CC used as a vaccine or diagnostic composition. The disease caused by
 CC Streptococcus that is prevented or treated may be meningitis. Nucleic
 CC acid encoding (I) may be used to recombinantly produce (I) and may be
 CC used in gene therapy. Antibodies to (I) are used for affinity
 CC chromatography, immunoassays, and distinguishing/identifying
 CC Streptococcus proteins.
 XX
 S0 Sequence 540 AA:
 Query Match 14.3%; Score 78; DB 23; Length 540;
 Best Local Similarity 100.0%; Pred. No. 3e-66;
 Matches 78; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 22 LAOTVAVTIGPRGVNVEKAFGSPLTINDGVTIAKEIELEDFENMGAKLVSEVASKTN 81
 DB 22 LAOTVAVTIGPRGVNVEKAFGSPLTINDGVTIAKEIELEDFENMGAKLVSEVASKTN 81
 QY 82 DIAGDGTATVLTQAI 99
 DB 82 DIAGDGTATVLTQAI 99
 RESULT 4
 AAM01101
 ID AAM01101 standard; Protein: 540. AA.
 AC AAM01101;
 DT 02-OCT-2001 (first entry)
 DE CFE 104 protein sequence.
 XX
 DE Antibacterial; vaccine; gene therapy; bacterial cell wall viability;
 KM CFE; CEG; Conserved Essential Gene; Bacterial Infection;
 KM antisense therapy; antibiotic resistance.
 OS Streptococcus pneumoniae.
 XX
 FN WO200149721-A2.
 PD 12-JUL-2001.
 PF 29-DEC-2000; 2000WO-US35604.
 PR 30-DEC-1999; 99US-0174089.
 PA (BRIM) BRISTOL-MYERS SQUIBB CO.
 PA Dougherty TJ, Pucci MJ, Dougherty BA, Davison DB, Brucoleri RE;
 PI Thannasi JA;
 XX
 DR WPI: 2001-496721/54.
 DR N-PSDB: AAH90800.
 XX Nucleic acids encoding conserved essential genes involved in bacterial
 PT replication which are potential targets for the treatment of antibiotic
 PT resistant bacterial infections -
 XX
 PS Claim 27; Pages 356-358; 380pp; English.

CC The present invention relates to nucleic acids (AAH90701-AAH90918).
 CC encoding polypeptides (AAH01002-AAH0114), which are essential for the
 CC viability of a bacterial cell wall. The acronym CFE stands for "CFE For
 CC Expression", where CFE stands for "Conserved Essential Gene". The nucleic
 CC acids are useful for detecting the presence of proteins essential for the
 CC viability of a bacterial cell wall in samples such as cells, tissues,
 CC biological fluids, blood, serum, nose, ear or throat swabs with ligands,
 CC and for detecting corresponding target nucleic acid molecules with
 CC complementary sequences. The nucleic acids are also useful for
 CC determining whether a genomic nucleotide sequence of interest is
 CC essential for viability of a bacterial cell or whether it resides within
 CC an operon. By integrating an exogenous nucleotide sequence comprising a
 CC portion of an open reading frame of the genomic sequence of interest
 CC (comprising 200-500 base pairs) into the genomic sequence of interest
 CC which confers a selectable phenotype to the cell, and determining cell
 CC viability with a selection agent such as chloramphenicol. The nucleic
 CC acids and proteins are also useful as vaccines and for treating bacterial
 CC infections with gene therapy and antisense therapy. The nucleic acids
 CC also enable identification of targets suitable for the treatment of
 CC antibiotic resistant bacterial infections.

XX Sequence 540 AA;

Query Match 12.8%; Score 70; DB 22; Length 540;
 Best Local Similarity 100.0%; Pred. No. 1.6e-58;

Matches 70; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 242 NRPLIIADVDGEALPTLVLNKIRGTNNVAVKAPGDRRKAMEDIAITGCTVITE 301
 DB 242 NRPLIIADVDGEALPTLVLNKIRGTNNVAVKAPGDRRKAMEDIAITGCTVITE 301
 OY 302 DLGLEKDAT 311
 DB 302 DLGLEKDAT 311

RESULT 5

AAV23902
 ID AAV23902 standard; Protein: 541 AA.

AC AAV23902;

DT 22-SEP-1999 (first entry)

DE Streptococcus pneumoniae heat shock protein (Hsp)60-2.

KW Heat shock protein; Hsp60-2; immune response; immunological carrier;
 cancer control; tumour; sarcoma; cancer; gene therapy.

OS Streptococcus pneumoniae.

PN MO9935270-A1.

PD 15-JUL-1999.

PF 29-DEC-1998; 98WO-CA01203.

PR 31-DEC-1997; 97US-0001737.

PI (STRE-) STRESSGEN BIOTECHNOLOGIES CORP.

PA Mizzen L, Wisniewski J;

DR WPI; 1999-430397/36.

DR N-PSDB; AAX86153.

PT New nucleic acid encoding heat shock protein-60 from Streptococcus,
 useful in vaccines, as carriers for other immunogens, as anticancer

PS Claim 11; Fig 2A-B; 176pp; English.

CC The present sequence represents a heat shock protein, designated Hsp60-2.

CC The protein, its fragments, variants and fusion proteins, are
 CC used to elicit or enhance an immune response against Streptococcus,
 CC and to elicit a similar response to a target antigen fused to the
 CC protein. Unlike other immunological carriers, Hsp60 proteins are not
 CC immunosuppressive so provide an increased response to any conjugated or
 CC fused antigen. Also, where used for cancer control, they lack the side
 CC effects associated with endotoxins. They can also be used to detect
 CC specific antibodies and in treatment or prevention of tumours
 CC (e.g. sarcoma or cancers of breast, ovary, prostate, lung, pancreas or
 CC liver). The Hsp60 polynucleotide is used for recombinant production
 CC of the protein, as a source of primers and probes for detecting
 CC streptococci in standard hybridization/amplification assays, and
 CC therapeutically in gene therapy vectors.

XX Sequence 541 AA;

Query Match 12.8%; Score 70; DB 20; Length 541;
 Best Local Similarity 100.0%; Pred. No. 1.6e-58;

Matches 70; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 242 NRPLIIADVDGEALPTLVLNKIRGTNNVAVKAPGDRRKAMEDIAITGCTVITE 301
 DB 242 NRPLIIADVDGEALPTLVLNKIRGTNNVAVKAPGDRRKAMEDIAITGCTVITE 301
 OY 302 DLGLEKDAT 311
 DB 302 DLGLEKDAT 311

RESULT 6

AAH31619
 ID AAB31619 standard; Protein: 641 AA.

AC AAB31619;

DT 30-APR-2001 (first entry)

DE Amino acid sequence of Hsp65-E7 fusion protein.

KW Heat shock protein; Hsp; Th1 response; Th1 cell; CD4+ T lymphocyte cell;
 lymphocyte; Hsp65; Hsp40; Hsp10; Hsp60; Hsp71; microbial pathogen;

KW E7 protein.

OS Synthetic.

OS Streptococcus pneumoniae.

OS Human papillomavirus.

PN WO200104344-A2.

PD 18-JAN-2001.

PF 10-JUL-2000; 2000WO-US18828.

PR 08-JUL-1999; 99US-0143757.

PI (STRE-) STRESSGEN BIOTECHNOLOGIES CORP.

PA Siegel M, Chu NR, Mizzen LA;

DR WPI; 2001-138361/14.

DR N-PSDB; AAF25036.

PT Screening for compounds that stimulate Th1-like responses in CD4+ T
 lymphocyte cells

PS Example 15; Fig 15A-B; 88pp; English.

CC The present sequence represents a fusion protein comprising a
 CC Streptococcus pneumoniae heat shock protein (Hsp) 65 fused to a HPV16 E7
 CC protein. The fusion protein is used in the method of the invention. The
 CC specification describes a method of determining whether a compound
 CC stimulates a Th1-like response. Th1 cells are a subset of CD4+
 CC T lymphocyte cells. The method comprises contacting naive lymphocytes

CC In vitro with a fusion protein comprising at least a fragment of Hsp.
 CC and then detecting the Th1-like response exhibited by the cell sample.
 CC The proteins which may be used in the method of the invention are Hsp65,
 CC Hsp40, Hsp10, Hsp60, and Hsp71. The method may be used to identify
 CC compounds that stimulate Th1-like responses in response to microbial
 CC pathogens.

XX Sequence 641 AA;

Query Match 12.8%; Score 70; DB 22; Length 641;
 Best Local Similarity 100.0%; Pred. No. 1.9e-58;
 Matches 70; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 242 NRPLIADVDVGEALPTLVNKRGTFFNVAVKAPGFCRRKAMLEDAITLGTGYTTE 301
 DB 242 NRPLIADVDVGEALPTLVNKRGTFFNVAVKAPGFCRRKAMLEDAITLGTGYTTE 301
 OY 302 DGLGELKDAT 311
 DB 302 DGLGELKDAT 311

RESULT 7
 ABB53701
 ID ABB53701 standard; Protein; 542 AA.

XX ABB53701;
 XX 16-MAY-2002 (first entry)
 XX Lactococcus lactis protein groEL.
 XX Lactococcus lactis protein groEL.
 XX Biosynthesis; biodegradation; lactic bacterium; yogurt; cheese.

XX Lactococcus lactis IL1403.
 XX FR2807446-A1.
 XX 12-OCT-2001.

XX 11-APR-2000; 2000FR-0004630.
 XX 11-APR-2000; 2000FR-0004630.

PA (INRG) INRA INST NAT RECH AGRONOMIQUE.

PI Bolocline A, Sorokline A, Renault P, Ehrlich SD;

DR WPI; 2002-043418/06.

PT New nucleotide sequence useful in the identification of Lactococcus
 PT lactis and related species.

PS Claim 6; SEQ ID No 403; 2504pp; French.

CC The present invention is related to a Lactococcus lactis nucleotide
 CC sequence (AB530521) and related proteins (AB53300-AB535621). The
 CC nucleic acid sequence is useful in the detection and/or amplification of
 CC related species. The proteins, particularly to identify Lactococcus lactis or
 CC biosynthesis or biodegradation of a composition of interest. The
 CC invention helps research in lactic bacteria, particularly useful in the
 CC production of yogurt and cheese.
 CC Note: The sequence data for this patent is based on equivalent patent
 CC WO200177334 (published 18-OCT-2001) which is available in electronic
 CC format directly from WIPO at ftp.wipo.int/pub/published_pcl_sequences.

XX Sequence 542 AA;

Query Match 10.3%; Score 56; DB 23; Length 542;
 Best Local Similarity 100.0%; Pred. No. 5.1e-45;
 Matches 56; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 44 GSPILINDSVTIANKIELEDFHFMGAKLVSEVASKNDIAGDGTATVLTQAIY 99
 DB 44 GSPILINDSVTIANKIELEDFHFMGAKLVSEVASKNDIAGDGTATVLTQAIY 99

RESULT 8

ID ABB49241 standard; Protein; 542 AA.

XX ABB49241;
 XX 05-FEB-2002 (first entry)

XX Listeria monocytogenes protein #1945.
 XX Antibacterial; gene therapy; vaccine; biosynthesis; biodegradation;
 XX vitamin B12; bacterial infection; disease.

XX Listeria monocytogenes.
 XX WO200177335-A2.
 XX 18-OCT-2001.

XX 11-APR-2001; 2001NO-FR01118.
 XX 11-APR-2000; 2000FR-0004629.

XX (INSP) INST PASTEUR.
 XX Buchrieser C, Frangeul L, Couve E, Rusniok C, Fsihi H, Dehoux P;
 XX Dussurget O, Chetoui M, Nedjari H, Glaser P, Kunst F, Cossart P;
 XX Daniels J, Goebel W, Kreft J, Kuhn M, Ng E, Vazquez-Boland JA;

PI Dominguez-Bernal G, Garrido-Garcia P, Tierrez-Martinez A, Amend A;
 PI Chakraborty T, Dommann E, Hahn T, Berche P, Chardit A, Durant L;
 PI Perez-Diaz J, Baquero F, Garcia Del Portillo F, Gomez-Lopez N;
 PI Madueno E, De Pablos B, Wehland J, Kaerst U, Entian K, Hauf J;
 PI Rose M, Voss H;
 XX WPI; 2002-010914/01.

PT Genomic sequence for Listeria monocytogenes, useful e.g. for treatment
 PT and prevention of Listeria and related bacterial infections, and
 PT related polypeptides

PS Claim 6; SEQ ID No 1946; 192pp; French.

CC The present invention relates to the genome sequence of Listeria
 CC monocytogenes EGD-e (see AB03041). The genome sequence and fragments of
 CC it are useful for selecting probes and primers for detecting genes in L.
 CC monocytogenes and related organisms, and for studying genetic
 CC polymorphisms and other genomes. The present sequence is a protein
 CC encoded by the genome sequence of the present invention. Proteins
 CC expressed from the genome sequence are useful for raising specific
 CC antibodies, identification of L. monocytogenes and related organisms, and
 CC for biosynthesis and biodegradation, especially biosynthesis of vitamin
 CC B12. The genome sequence and proteins encoded by it are also useful for
 CC selecting compounds that regulate gene expression and cell replication
 CC and modulate L. monocytogenes-related diseases. In addition, the genome
 CC sequence and proteins encoded by it are useful in pharmaceutical and
 CC vaccine compositions for the treatment or prevention of infections by L.
 CC monocytogenes and related organisms.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pcl_sequences.

XX Sequence 542 AA;

Query Match 5.7%; Score 31; DB 23; Length 542;
 Best Local Similarity 100.0%; Pred. No. 6.6e-21;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 266 RGTENVAVKAPGFCRRKAMLEDAITLGTG 296

```

DB      266  RGTENVAVAKPGFGDRRKAMLEIDIALITG 296
          |||
RESULT 9
ID      AAY23916
AY      AAY23916 standard; Protein: 539 AA.
XX
XX      AAY23916;
AC
XX      22-SEP-1999 (first entry)
DT
XX
XX      Amino acid sequence of a heat shock protein.
DE
XX      Heat shock protein: Hsp; immune response; immunological carrier;
KW      cancer control; tumour; sarcoma; cancer; gene therapy.
XX
XX      Staphylococcus aureus;
OS
XX      MO9935270-A1.
XX      15-JUL-1999.
XX
XX      29-DEC-1998; 98WO-CA01203.
XX
XX      31-DEC-1997; 97US-0001737.
XX
XX      (STRE-) STRESSGEN BIOTECHNOLOGIES CORP.
XX
XX      Mizzen L, Wisniewski J;
XX      WPI: 1999-430397/36.
XX
XX      New nucleic acid encoding heat shock protein-60 from Streptococcus;
PT      useful in vaccines, as carriers for other immunogens, as anticancer
PT      agents and for diagnosis
XX
XX      Disclosure; Fig 10A-E; 170pp; English.
XX
XX      AAY23905-30 represent heat shock proteins (Hsps). The specification
CC      describes Streptococcal Hsps, designated Hsp60. These proteins, their
CC      fragments, variants and fusion proteins, are used to elicit or enhance
CC      an immune response against Streptococcus, and to elicit a similar
CC      response to a target antigen fused to the protein. Unlike other
CC      immunological carriers, Hsp60 proteins are not immunosuppressive so
CC      provide an increased response to any conjugated or fused antigen. Also,
CC      where used for cancer control, they lack the side effects associated
CC      with endotoxins. They can also be used to detect specific antibodies
CC      and in treatment or prevention of tumours (e.g. sarcoma or cancers of
CC      breast, ovary, prostate, lung, pancreas or liver). The Hsp60
CC      polynucleotide is used for recombinant production of the protein, as
CC      a source of primers and probes for detecting streptococci in standard
CC      hybridization/amplification assays, and therapeutically in gene
CC      therapy vectors.
XX
XX      Sequence 539 AA:
SO
XX
XX      Query Match 4.8%; Score 26; DB 20; Length 539;
XX      Best Local Similarity 100.0%; Pred. No. 4.3e-16;
XX      Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY      356  SDFDRKLEQLAKGAVAYIKGA 381
DB      357  SDFDRKLEQLAKGAVAYIKGA 382
          |||
RESULT 10
ID      AAY37100 standard; Protein: 224 AA.
XX
XX      AAY37100;
AC
XX      07-OCT-1999 (first entry)
DT

```

```

XX      Amino acid sequence of a Chlamydia trachomatis protein.
DE
XX
XX      Vaccine; eye disease; conventional trachoma; nongonococcal
KW      paratrachoma; inclusion conjunctivitis; genital disease; peritphalitis;
KW      nongonococcal urethritis; epididymitis; cervicitis; salpingitis;
KW      bartholinitis; pneumonia; venereal lymphogranulomatosis.
XX
XX      Chlamydia trachomatis.
XX
XX      MO9928475-A2.
XX      10-JUN-1999.
XX
XX      27-NOV-1998; 98WO-IB01939.
XX
XX      04-NOV-1998; 98US-0107077.
XX      28-NOV-1997; 97FR-0015041.
XX      17-DEC-1997; 97FR-0016034.
XX
XX      (GEST ) GENSET.
XX
XX      Griffals R;
XX
XX      WPI: 1999-371125/31.
XX
XX      Genome sequence of Chlamydia trachomatis
XX
XX      Disclosure; Page 900; 1755pp; English.
XX
XX      AAY36754-Y37949 are encoded by open reading frames (ORFs) of the genome
CC      of Chlamydia trachomatis (see AAY01425). The polypeptides can be used as
CC      vaccines against Chlamydia trachomatis. Antisense and ribozyme sequences
CC      can also be used to control growth of the microorganism. Chlamydia
CC      trachomatis is responsible for a large number of diseases, e.g. eye
CC      diseases such as conventional trachoma, nongonococcal trachoma,
CC      paratrachoma, and inclusion conjunctivitis; genital diseases such as
CC      nongonococcal urethritis, epididymitis, cervicitis, salpingitis,
CC      peritphalitis, bartholinitis; pneumonia in breast feeding infants;
CC      and venereal lymphogranulomatosis. The polypeptides of the invention
CC      may be of use in treating these diseases.
XX
XX      Sequence 224 AA:
SO
XX
XX      Query Match 4.4%; Score 24; DB 20; Length 224;
XX      Best Local Similarity 100.0%; Pred. No. 1.6e-14;
XX      Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY      273  AVKAPGDRRKAMLEIDIALITG 296
DB      20  AVKAPGDRRKAMLEIDIALITG 43
          |||
RESULT 11
ID      AAM10977 standard; Protein: 419 AA.
XX
XX      AAM10977;
AC
XX      21-MAY-1997 (first entry)
DT
XX
XX      Dihydrofolate reductase-Chlamydia pneumoniae antigen fusion protein.
DE
XX      DHFR: dihydrofolate reductase; Chlamydia pneumoniae; pneumonia;
KW      antibody production; diagnosis; fusion protein.
XX
XX      Chlamydia pneumoniae (chimeric).
XX
XX      Key 1.160
XX      Region /note- "dihydrofolate reductase region"
XX      161..170
XX      /note- "peptide linker"
FT

```


FT Misc-difference 171..407
 XX /note= "Chlamydia pneumoniae antigen region"
 PM JP08294391-A.
 XX
 PD 12-NOV-1996.
 XX
 XX 28-APR-1995; 95JP-0106007.
 XX
 XX 28-APR-1995; 95JP-0106007.
 XX
 PA (HITB) HITACHI CHEM CO LTD.
 XX
 DR WPI; 1997-036901/04.
 XX
 PT Fusion protein comprising dihydrofolate reductase and Chlamydia
 PT pneumoniae antigen - useful in prodn. of C. pneumoniae antibodies
 PT for diagnosis of infection
 XX
 PS Claim 5; Page 14-15; 17pp; Japanese.
 XX
 CC AAM10977 is a dihydrofolate reductase (DHFR)-Chlamydia pneumoniae
 CC antigen fusion protein. Fusion proteins that may be made consist of at
 CC least 5 contiguous amino acids of the Chlamydia pneumoniae antigen
 CC linked to the N-terminus of a DHFR protein (see AAM10974). Fusion
 CC proteins produced are useful for the production of anti-C. pneumoniae
 CC antibodies which are useful in the diagnosis and treatment of infectious
 CC diseases caused by C. pneumoniae.
 XX
 SQ Sequence 419 AA;
 XX
 Query Match 4.4%; Score 24; DB 18; Length 419;
 Best Local Similarity 100.0%; Pred. No. 2,9e-14;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 273 AVKAPGFGRRKRAMEDIAITLTGG 296
 Db 243 AVKAPGFGRRKRAMEDIAITLTGG 266
 XX
 RESULT 12
 AAM1865
 ID AAM1865 standard; Protein; 419 AA.
 XX
 AC AAM1865;
 XX
 DF 17-APR-1997 (first entry)
 XX
 DE DHFR/Polypeptide B fusion protein #2.
 XX
 KM Dihydrofolate reductase; DHFR; C. pneumoniae; detection; antibody;
 KM fusion protein; antigen; diagnosis.
 XX
 OS Chlamydia pneumoniae.
 XX
 FH Key Location/Qualifiers
 FT Protein 1..160
 FT /label= DHFR
 FT 172..407
 FT /label= Polypeptide_B_residues_203-439
 XX
 PN JP08304403-A.
 XX
 PD 22-NOV-1996.
 XX
 XX 28-APR-1995; 95JP-0106012.
 XX
 XX 28-APR-1995; 95JP-0106012.
 XX
 PA (HITB) HITACHI CHEM CO LTD.
 XX
 DR WPI; 1997-056177/06.
 XX

PT Detection and determination of anti-Chlamydia pneumoniae antibody -
 PT using an antigenic polypeptide fused to the Chlamydia
 PT dihydrofolate reductase as the antigen
 XX
 PS Claim 5; Page 15-16; 17pp; Japanese.
 XX
 CC This sequence represents a fusion between C. pneumoniae polypeptide
 CC B and dihydrofolate reductase (DHFR). This protein was used in the
 CC method of the invention for the detection and determination of
 CC anti-Chlamydia pneumoniae antibody. DHFR and polypeptide B were
 CC combined directly or through an amino acid sequence to give a fusion
 CC protein to act as an antigen. The fusion protein may be used in
 CC a reagent which has a high reliability and which gives an exact
 CC diagnosis.
 XX
 SQ Sequence 419 AA;
 XX
 Query Match 4.4%; Score 24; DB 18; Length 419;
 Best Local Similarity 100.0%; Pred. No. 2,9e-14;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 273 AVKAPGFGRRKRAMEDIAITLTGG 296
 Db 243 AVKAPGFGRRKRAMEDIAITLTGG 266
 XX
 RESULT 13
 AAR13337
 ID AAR13337 standard; Protein; 544 AA.
 XX
 AC AAR13337;
 XX
 DF 17-DEC-2001 (updated)
 DF 22-OCT-1991 (first entry)
 XX
 DE Hyb protein.
 XX
 KM Antibodies; heat shock; hypersensitive; allergen; HSP60; GROES;
 KM GROEL.
 XX
 OS Chlamydia trachomatis serovar A.
 XX
 PN USN/531317-N.
 XX
 PD 09-JUL-1991.
 XX
 PF 31-MAY-1990; 90US-0143560.
 XX
 PR 31-MAY-1990; 90US-0531317.
 XX
 XX (USSH) NAT INST OF HEALTH.
 PA
 PA WPI; 1991-245693/33.
 DR N-PSDB; AAQ13137.
 DR
 XX
 PT DNA encoding HybA and HybB Chlamydia proteins - used to develop
 PT prods. for detection of and vaccines against Chlamydia infection.
 PT
 PS Disclosure: Fig 7; 51pp; English.
 XX
 CC The sequence was deduced from the second of two ORFs found in the
 CC hyp operon of clone pTAS71CC prepd. from C. trachomatis genomic DNA.
 CC It is the HybB hypersensitivity protein, analogous to the E. coli
 CC GroEL protein. It can be used to raise antibodies and to
 CC prepare vaccines for the treatment of Chlamydial infections. The
 CC protein also elicits a cell-mediated immune response so can be used
 CC as a skin test antigen.
 CC See also AAR13334-R13336.
 CC (Note: Revised entry submitted to correct the patent number format
 CC US Government-owned NIS applications to prevent clashes with ongo
 CC granted patent numbers. For further information please visit the
 CC web site at www.derwent.com/dwpi/updates/ntis_us.html.)
 XX

SQ Sequence 544 AA:

Query Match 4.4%; Score 24; DB 12; Length 544;
 Best Local Similarity 100.0%; Pred. No. 3.7e-14;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 273 AVKAPGFGDRRKAMLEDAIILTTGG 296
 |||||
 DB 275 AVKAPGFGDRRKAMLEDAIILTTGG 298

RESULT 14

ID AAR67383 standard; Protein; 544 AA.

XX AAR67383;

DT 22-JUN-1995 (first entry)

DE C. psittaci HypB gene product.

KM Urease; immunogen; vaccine; diagnostic; heat shock protein; HSP;

KM GroEL-like protein; Helicobacter felis.

OS Chlamydia psittaci.

PN MO9426901-A.

PD 24-NOV-1994.

PR 19-MAY-1994; 94MO-EP01625.

PR 19-MAY-1993; 93EP-0401309.

PR 19-NOV-1993; 93WO-EP03259.

PA (INRM) INST NAT SANTE & RECH MEDICALE.

PA (INSP) INST PASTEUR.

PI Ferrero R, Labigne A, Suerbaum S, Thiberge J;

DR WPI; 1995-006797/01.

PT DNA from Helicobacter pylori and Helicobacter felis - used to

PT develop prods. for detection, treatment and prevention of

PT Helicobacter infection

PS Disclosure: Fig. 7A(1-11); 168pp; English.

XX The sequence of the Helicobacter pylori heat shock protein A

CC (given in AAR67374) was compared to that of other GroEL-like

CC proteins from Legionella pneumophila (AAR67381), Escherichia coli

CC (AAR67382), Chlamydia psittaci (AAR67383), Mycobacterium leprae

CC (AAR67384) and human mitochondrial protein PI (AAR67385), and regions

CC of homology were identified.

SQ Sequence 544 AA:

Query Match 4.4%; Score 24; DB 16; Length 544;

Best Local Similarity 100.0%; Pred. No. 3.7e-14;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 273 AVKAPGFGDRRKAMLEDAIILTTGG 296

DB 275 AVKAPGFGDRRKAMLEDAIILTTGG 298

AAW10975

ID AAW10975 standard; Protein; 544 AA.

XX AAW10975;

AC AAW10975;

XX 21-MAY-1997 (first entry)

XX Chlamydia pneumoniae antigen used as DHFR-linked fusion protein.
 DE DHFR: dihydrofolate reductase; Chlamydia pneumoniae; pneumonia;
 KW antibody production; diagnosis; fusion protein.
 XX Chlamydia pneumoniae.

OS Key Location/Qualifiers
 FH Misc-difference 25 /note- "given as Gie in three letter amino
 FT acid code in the specification"

JP08294391-A.

PD 12-NOV-1996.

PR 28-APR-1995; 95JP-0106007.

PR 28-APR-1995; 95JP-0106007.

PA (HITB) HITACHI CHEM CO LTD.

DR WPI; 1997-036901/04.

PT Fusion protein comprising dihydrofolate reductase and Chlamydia
 PT pneumoniae antigen - useful in prodn. of C. pneumoniae antibodies
 PT for diagnosis of infection

PS Claim 1; Page 11-12; 17pp; Japanese.

XX AAW10974 encodes a 544 residue Chlamydia pneumoniae antigen, at least

CC 5 contiguous amino acids of which are fused to a dihydrofolate

CC reductase (DHFR) enzyme. Fusion proteins produced are useful for the

CC production of anti-C. pneumoniae antibodies which are useful in the

CC diagnosis and treatment of infectious diseases caused by C. pneumoniae.

SQ Sequence 544 AA:

Query Match 4.4%; Score 24; DB 18; Length 544;

Best Local Similarity 100.0%; Pred. No. 3.7e-14;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 273 AVKAPGFGDRRKAMLEDAIILTTGG 296

DB 275 AVKAPGFGDRRKAMLEDAIILTTGG 298

Search completed: April 8, 2003, 14:35:09

Job time : 81 secs